Rituximab Therapy for Adult Refractory Systemic Lupus Erythematosus with Neurological and/or Psychiatric Presentations: A PRISMACompliant Meta-Analysis
- 1 June 2025
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Rheumatology Reviews
- Vol. 21 (3) , 336-346
Abstract
Background: Rituximab (RTX) is used off-label for refractory cases of Systemic lupus erythematosus (SLE) with extrarenal activity, including neurological and/or psychiatric (N/P) presentations. However, evidence from randomized controlled trials is limited. Objective: This study aimed to conduct a pooled analysis of the effectiveness and safety of RTX therapy for adult refractory SLE with N/P manifestations. Methods: Electronic searches in databases and statistical analysis were conducted in this study. Results: Electronic searches in PubMed, Epistemonikos, and ICTRP in May 2023 identified 20 studies (25 reports). A total of 59 patients (53 females; 90%) were included, with a mean age of 33.5±10.6 years and a median disease duration of 3.5 years (range, 0.08 to 25.0) who were followed up post-RTX therapy for a median time of 12 months (range, 3.0 to 46.2). The rate of clinical response (partial or major) was 90% (95% CI, 83 to 96) (n = 57 patients). A third of responders relapsed after a median time of 9.5 months (range, 3.0 to 33.0). Pooled pre-RTX/post-RTX scores for Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) (n = 13) were 19±15/7±5 and for neurological British Isles Lupus Assessment Group (BILAG) (n = 29) were A/D (13), A/C (5), B/D (7), B/C (2), and A/A (2). Patients without mood disorder had a higher chance of clinical response {relative risk (RR) 1.4 (1.03 to 1.48)}. Patients who benefited the most from RTX therapy were those with psychosis (a higher chance of major clinical response; RR 1.9 (1.02 to 2.34)), without acute confusional state (a lower chance of relapse; RR 0.08 (0.006 to 0.791)), and with disease duration <3 years (a lower chance of relapse; RR 0.18 (0.014 to 0.992)). Infection rate during treatment was 33% (7/21). Conclusions: RTX therapy had good effectiveness. The pooled evidence for safety outcomes was limited and of low certainty.Keywords
This publication has 52 references indexed in Scilit:
- SLE ‐associated myelitis successfully treated by rituximabClinical Case Reports, 2022
- Introduction, comparison, and validation of Meta‐Essentials: A free and simple tool for meta‐analysisResearch Synthesis Methods, 2017
- Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future PerspectivesDrugs, 2016
- The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosusClinical Rheumatology, 2015
- Elevated Serum BAFF Levels Are Associated With Rising Anti–Double‐Stranded DNA Antibody Levels and Disease Flare Following B Cell Depletion Therapy in Systemic Lupus ErythematosusArthritis & Rheumatism, 2013
- Rituximab: rescue therapy in life-threatening complications or refractory autoimmune diseases: a single center experienceRheumatology International, 2012
- Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registryArthritis & Rheumatism, 2010
- A retrospective seven‐year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college london hospital: The first fifty patientsArthritis Care & Research, 2009
- Long‐term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re‐treatmentArthritis & Rheumatism, 2006
- SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody)Rheumatology International, 2005